Earnings

ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate

Aug 3, 2026 · 04:57 PM ET· updated 2h ago

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share

Why It Matters

ORIC lost more money per share than experts predicted, but the good news is they're losing less money overall than they did last year. When a company is improving even if it still misses targets, watch whether they're getting closer to being profitable.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ORIC10.62

-0.45 (-4.10%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.